Laurel Yap, MD
Nephrology · Flushing, NYNPI 1801058490
Payments from drug & device makers
Across 582 payments — averaging $22.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Calliditas Therapeutics US Inc.$1K
- Vifor Pharma, Inc.$1000
- OPKO Pharmaceuticals, LLC$955
- Amgen$879
- plus $6K from 23 others
What the payments were for
- Food & beverage$12,23893%
- Education$8627%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 108 | $2,465 |
| Otsuka America Pharmaceutical, Inc. | 59 | $1,115 |
| Calliditas Therapeutics US Inc. | 35 | $1,090 |
| Vifor Pharma, Inc. | 55 | $1,000 |
| OPKO Pharmaceuticals, LLC | 43 | $955 |
| Amgen(2 entities) | 37 | $879 |
| GSK | 33 | $770 |
| Akebia Therapeutics Inc | 28 | $767 |
| ANI Pharmaceuticals, Inc. | 34 | $630 |
| Travere Therapeutics, Inc. | 17 | $574 |
| Boehringer Ingelheim | 23 | $549 |
| Bayer | 19 | $375 |
| Mallinckrodt Hospital Products Inc. | 13 | $294 |
| Amarin Pharma, Inc. | 14 | $285 |
| Novartis | 11 | $241 |
| Fresenius USA Marketing, Inc. | 12 | $233 |
| Aurinia Pharma U.S., Inc. | 10 | $201 |
| Sumitomo Pharma America, Inc. | 5 | $117 |
| Novo Nordisk | 6 | $112 |
| Fresenius USA Manufacturing, Inc. | 4 | $92 |
| Ardelyx, Inc. | 4 | $90 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $67 |
| Lilly USA, LLC | 2 | $56 |
| AbbVie | 2 | $40 |
| Sanofi | 1 | $24 |
| IBSA Pharma Inc. | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Merck | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,101 in reported general payments places this provider in the 80th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RayaldeeCalcifediol | 377 | $451,623 |
| FarxigaDapagliflozin Propanediol | 665 | $439,409 |
| JardianceEmpagliflozin | 265 | $169,910 |
| KerendiaFinerenone | 231 | $161,511 |
| VascepaIcosapent Ethyl | 417 | $160,621 |
| LokelmaSodium Zirconium Cyclosilicate | 184 | $106,523 |
| VelphoroSucroferric Oxyhydroxide | 36 | $98,329 |
| RetacritEpoetin Alfa-Epbx | 108 | $75,535 |
| JanuviaSitagliptin Phosphate | 115 | $68,352 |
| XphozahTenapanor Hcl | 20 | $67,198 |
| RybelsusSemaglutide | 71 | $65,971 |
| AuryxiaFerric Citrate | 34 | $64,324 |
| DapagliflozinDapagliflozin Propanediol | 79 | $54,772 |
| VeltassaPatiromer Calcium Sorbitex | 74 | $41,880 |
| TradjentaLinagliptin | 50 | $30,011 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $2,465 | $545,932849 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $955 | $451,623377 claims |
| Boehringer IngelheimJardiance, Tradjenta | $549 | $199,922315 claims |
| BayerKerendia | $375 | $161,511231 claims |
| Fresenius USA Marketing, Inc.Velphoro | $233 | $98,32936 claims |
| Novo NordiskRybelsus, Ozempic | $112 | $93,24399 claims |
| MerckJanuvia | $18 | $68,352115 claims |
| Akebia Therapeutics IncAuryxia | $767 | $64,32434 claims |
| AbbVieCreon, Linzess | $40 | $24,89037 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $117 | $12,23724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 935 nephrology providers in New York.
Other nephrology in Flushing
- Joji TokitaNew York$8.4M
- Krzysztof KirylukNew York$6.7M
- David BernardNew York$6M
- Andrew BombackNew York$3.4M
- Pietro CanettaNew York$3.2M
- Robert LynnBronx$2M
- Jodumutt BhatMaspeth$1.5M
- Gerald AppelNew York$1.5M
- David CharytanNew York$1.3M
- Frank CortazarAlbany$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.